{"id":"W2978821371","doi":"10.1093/annonc/mdz260.065","title":"Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK+ NSCLC in the phase II ALTA trial","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Clinical endpoint; Crizotinib; Refractory (planetary science); Gastroenterology; Stock options; Randomized controlled trial; Surgery; Lung cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001128617,0.0008423858,0.001709782,0.0002356979,0.0002492931,0.001185099,0.0004679882,0.0007316425,0.00367272],"category_scores_gemma":[0.0007870898,0.0003265874,0.001666824,0.0004216446,0.0005537017,0.0009635051,0.0003487168,0.003217425,0.0008243667],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006090094,"about_ca_system_score_gemma":0.0008507201,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009743539,"about_ca_topic_score_gemma":0.003791613,"domain_scores_codex":[0.9997354,0.0001175211,0.00001733584,0.00004304238,0.00001898401,0.00006782207],"domain_scores_gemma":[0.9996915,0.0000562638,0.00006590646,0.00002057333,0.0000173215,0.000148546],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8880058,0.003081801,0.006398404,0.001123785,0.00386947,0.0002053231,0.0001722611,0.001758484,0.01169817,0.0005030683,0.005421575,0.07776175],"study_design_scores_gemma":[0.8175173,0.131381,0.03147858,0.0002013423,0.005422228,0.000556528,0.000285127,0.002059143,0.002027126,0.000942819,0.008061394,0.00006745535],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860235,0.00778984,0.0001924999,0.001219432,0.0003110504,0.0003164146,0.0008747834,0.0001007863,0.003171626],"genre_scores_gemma":[0.9912305,0.003563775,0.0003499381,0.001205887,0.0001749056,0.0003076989,0.001069008,0.00002234026,0.002076008],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00367272,"threshold_uncertainty_score":0.01228648,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03817094178693786,"score_gpt":0.4194097159825595,"score_spread":0.3812387741956217,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}